-based applicability may
be limited by economic considerations. This should be
considered by clinicians when electing how to treat patients with carotid artery disease, and it may also inï¬‚uence patient decision-making. It seems clear that a
reduction in the costs associated with carotid stents
and associated other necessary endovascular tools may
be necessary,674 and/or reimbursement by payors will
need to match associated costs.

REFERENCES
1. Esl